Plant Name: Ophiorrhiza liukiuensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.131E-08 | 1.458E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.526E-08 | 1.971E-04 | AKR1B1, AKR1B10, CYP1A2, CYP2D6, CYP3A4, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.240E-07 | 2.999E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.559E-07 | 5.573E-04 | CA12, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.919E-07 | 1.800E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.186E-06 | 3.400E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.882E-06 | 5.008E-03 | AKR1B1, AKR1B10, ALDH1A1, CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.971E-06 | 5.008E-03 | CA12, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.370E-06 | 5.008E-03 | CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.333E-06 | 7.604E-03 | CA12, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 7.333E-06 | 7.604E-03 | AKR1B1, AKR1B10, ALDH1A1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.853E-06 | 7.773E-03 | CYP1A2, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.443E-07 | 2.479E-05 | CA12; CA7; CA9 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.302E-05 | 3.980E-04 | CASP7; CASP1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.157E-05 | 3.980E-04 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.581E-05 | 3.980E-04 | CYP2D6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.058E-05 | 3.980E-04 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.316E-05 | 3.980E-04 | CASP7; CASP1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.819E-04 | 2.500E-03 | AKR1B10; CYP1A2; ALDH1A1; AKR1B1; CYP3A4; HSD17B10 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.631E-04 | 2.500E-03 | CASP7; MAPT; HSD17B10 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.724E-04 | 2.500E-03 | CYP1A2; CYP3A4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.917E-04 | 2.500E-03 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 4.212E-04 | 2.527E-03 | AKR1B10; AKR1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.131E-03 | 5.428E-03 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 3.323E-04 | 2.500E-03 | AKR1B10; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.056E-03 | 5.428E-03 | CASP1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.093E-03 | 5.428E-03 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.633E-03 | 6.915E-03 | NR1H4; CYP3A4 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.329E-03 | 5.981E-03 | CASP1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.863E-03 | 1.391E-02 | CASP7; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.170E-03 | 8.680E-03 | CYP1A2; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.176E-03 | 2.021E-02 | CASP7; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.383E-03 | 9.032E-03 | CASP1; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 7.149E-03 | 2.238E-02 | CASP7; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 9.497E-03 | 2.849E-02 | CASP1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.243E-03 | 1.455E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |